Lexeo Therapeutics (LXEO) Chardan's 10th Annual Healthcare Conference summary

Clinical pipeline and milestones

• LX2006 is the lead program for Friedreich’s ataxia (FA) cardiomyopathy; its registrational SUNRISE-FA 2 study began enrolling at the end of Q2.

• Phase I/II data showed effects on left ventricular mass index, multiple biomarkers and neurological function measured by mFARS.

• LX2006 phase III top-line data are expected in 2H 2027, followed by a planned BLA filing in H1 2028.

• LX2020 targets PKP2-associated arrhythmogenic cardiomyopathy; phase I/II data showed effects on NSVT and PVCs with a favorable safety profile.

• Preclinical programs include LX2021 for desmoplakin cardiomyopathy and LX2022 for hypertrophic cardiomyopathy.

PKP2 data and regulatory outlook

• January data showed PVCs down 14% and NSVT down 22%; two patients with nine-month follow-up had a 65% NSVT reduction.

• Q4 update is expected to include most high-dose patients with at least 12 months of follow-up, plus a regulatory update; most of seven high-dose patients are expected to reach 12 months, except one or two.

• NSVT is viewed as the most clinically meaningful endpoint; a 35%-40% reduction was described as a target to exceed the 20%-30% effects associated with current drug treatments.

• FDA discussions on endpoints and pivotal design are ongoing; an August RMAT designation submission included contemporary data centered substantially on NSVT.

• Arrhythmia effects are expected to deepen over time, with 12 months viewed as an initial point to assess response; structural changes may take longer, and one patient showed increased RVEF.

FA strategy and study execution

• LX2006 reaches peripheral nervous system components, including skeletal muscle and dorsal root ganglia, but not the brain; the Mantle portfolio adds programs intended to reach the brain and potentially complement LX2006 in FA.

• CLARITY-FA serves as a feeder into SUNRISE-FA 2, with identical inclusion criteria; eligible participants may roll over if they test negative for neutralizing antibodies and their treatment site is activated.

• CLARITY-FA had 19 active sites across eight countries and 22 enrolled patients; SUNRISE-FA 2 is designed for 13 treated and 13 untreated control patients.

• Confirmatory approval discussions continue; potential evidence may combine cardiac endpoints and mFARS.